ACTB Monoclonal Antibody
-
中文名稱：ACTB鼠單克隆抗體
-
貨號(hào)：CSB-MA847175
-
規(guī)格：￥1760
-
其他：
產(chǎn)品詳情
-
產(chǎn)品描述：ACTB單克隆抗體（CUSABIO貨號(hào)：CSB-MA847175）是一款靶向β-肌動(dòng)蛋白的高特異性科研用抗體，該靶點(diǎn)作為細(xì)胞骨架核心蛋白，廣泛參與細(xì)胞形態(tài)維持、運(yùn)動(dòng)及分裂等關(guān)鍵生物學(xué)過程，是分子生物學(xué)實(shí)驗(yàn)中重要的內(nèi)參指標(biāo)。本產(chǎn)品采用雜交瘤技術(shù)制備，經(jīng)嚴(yán)格驗(yàn)證可同時(shí)識(shí)別人類、大鼠、小鼠、猴、犬、雞、倉(cāng)鼠、兔、豬、羊等10個(gè)物種的ACTB蛋白，適用于ELISA、Western Blot、免疫組化（IHC）和免疫熒光（IF）等多種實(shí)驗(yàn)體系，尤其在跨物種比較研究和多平臺(tái)實(shí)驗(yàn)結(jié)果驗(yàn)證中展現(xiàn)卓越性能。在Western Blot中能清晰檢測(cè)約42kDa的目標(biāo)條帶，免疫組化實(shí)驗(yàn)可精準(zhǔn)定位組織切片中的β-肌動(dòng)蛋白表達(dá)，而免疫熒光應(yīng)用則支持亞細(xì)胞定位分析。該抗體為生命科學(xué)研究提供高重復(fù)性的檢測(cè)工具，廣泛應(yīng)用于細(xì)胞生物學(xué)、分子機(jī)制研究、蛋白相互作用分析及疾病模型構(gòu)建等領(lǐng)域，助力科研人員實(shí)現(xiàn)精準(zhǔn)的蛋白表達(dá)量標(biāo)準(zhǔn)化和實(shí)驗(yàn)質(zhì)量控制。
-
別名：ACTB; BRWS1; PS1TP5BP1
-
宿主：Mouse
-
反應(yīng)種屬：Human,Rat,Mouse,Monkey,Dog,Chk,Hamster,Rabbit,Pig,Sheep
-
免疫原：
-
免疫原種屬：Homo sapiens (Human)
-
克隆類型：Monoclonal
-
純化方式：Antigen Affinity Purified
-
克隆號(hào)：3B4
-
濃度：It differs from different batches. Please contact us to confirm it.
-
產(chǎn)品提供形式：Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
-
應(yīng)用范圍：ELISA,WB,IHC,IF
-
推薦稀釋比：
Application Recommended Dilution WB 1:500-1:5000 IHC 1:50-1:500 IF 1:50-1:200 -
Protocols：
-
儲(chǔ)存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評(píng)價(jià)
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
